Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 60K | 11K | 6K | 25K | 647K |
| Gross Profit | -25K | 4K | -257K | 2K | -349K |
| Operating Income | -1M | -791K | -2M | -6M | -2M |
| EBITDA | -1M | -791K | -3M | -6M | -2M |
| Net Income | -1M | -906K | -3M | -6M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Real Brands, Inc. (RLBD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +443.0%, EPS growth of -66.7%, a dividend yield of 0.0%. What stands out right now is revenue +443.0%, EPS -66.7%, free cash flow +74.1% with operating margin -1970.1% and ROIC 481.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLBD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLBD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLBD Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLBD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$646.6K
+2530.4% YoY
FY Net Income
-$2.0M
+67.5% YoY
Free Cash Flow
-$2.5M
-132.6% YoY
Revenue Growth
+443.0%
EPS Growth
-66.7%
Gross Margin
-41.6%
Net Margin
-2203.4%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 60K | 11K | 6K | 25K | 647K |
| Gross Profit | -25K | 4K | -257K | 2K | -349K |
| Operating Income | -1M | -791K | -2M | -6M | -2M |
| EBITDA | -1M | -791K | -3M | -6M | -2M |
| Net Income | -1M | -906K | -3M | -6M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79K | 3K | 197K | 248K | 92K |
| Total Assets | 1M | 1M | 1M | 2M | 1M |
| Total Liabilities | 3M | 2M | 1M | 1M | 460K |
| Shareholder Equity | -1M | -753K | -12K | 696K | 551K |
| Total Debt | 1M | 717K | 489K | 655K | 200K |
| Net Debt | 977K | 714K | 292K | 407K | 108K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-227.2% YoY
Capital Expenditures
637K
-25.0% YoY
Free Cash Flow
3M
-132.6% YoY
Key ratios
Gross Margin
-41.6%
Operating Margin
-1970.1%
Net Margin
-2203.4%
ROE
129.5%
Debt / Equity
-0.81x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.